Smith et al. use clinical development screen and whole genome siRNA-reverse genetics phenotypic screen to identify ROCK2, as a modulator of cilia formation and function via its effects on actin cytoskeleton remodelling. Repurposing ROCK2 is a viable treatment for ciliopathies, for which a limited therapeutic option is available.
- Claire E. L. Smith
- Andrew J. Streets
- Colin A. Johnson